摘要
目的探讨唑来膦酸联合化疗对非小细胞肺癌(NSCLC)骨转移临床疗效及炎性因子水平的影响。方法研究时间为2015年6月—2017年8月,采用回顾性研究方法,选择在重庆市开州区人民医院诊治的NSCLC骨转移患者102例,根据治疗方法的不同分为观察组52例与对照组50例,对照组给予含铂类方案化疗,观察组在对照组治疗的基础上给予唑来膦酸治疗,两组都治疗观察4周。观察比较两组的临床疗效、骨痛评分、炎症因子及不良反应情况。结果观察组的总有效率为84.6%,显著高于对照组的52.0%,差异有统计学意义(P<0.05)。治疗后观察组与对照组的骨痛评分都显著低于治疗前,同组治疗前后比较差异有统计学意义(P<0.05);观察组的评分也显著低于对照组,差异有统计学意义(P<0.05)。治疗后两组的血清肿瘤坏死因子-α(TNF-α)水平显著低于治疗前,同组治疗前后比较差异有统计学意义(P<0.05);观察组也显著低于对照组,差异有统计学意义(P<0.05)。两组治疗期间的不良反应分别为发热、寒颤、骨髓抑制、胃肠道反应,两组对比差异无统计学意义。结论唑来膦酸联合化疗在NSCLC骨转移中的应用能提高临床疗效与缓解疼痛,且不会增加不良反应的发生,其作用机制与降低炎性因子表达水平有关。
Objective To investigate the effects of zoledronic acid combined with chemotherapy on the clinical efficacy and inflammatory factors in patients with non-small cell lung cancer(NSCLC) with bone metastases. Methods From June 2015 to August 2017, 102 patients of NSCLC bone metastases were selected in our hospital and were divided into the 52 patients in the observation group and the 50 patients in the control group accorded to the different treatment methods. The control group were given the platinum group therapy, the observation group were treated with zoledronic acid on the basis of the control group, and the two groups were treated for 4 weeks. Results The total effective rate in the observation group were 84.6%, which were significantly higher than that in the control group(72%)(P < 0.05). After treatment, the bone pain scores in the observation group and the control group were significantly lower than those before treatment(P < 0.05), and the score in the observation group were also significantly lower than that in the control group(P < 0.05). The serum TNF-ɑ content in the two groups after treatment were significantly lower than that before treatment(P < 0.05), the observation group were significantly lower than that of control group(P < 0.05). The adverse reactions in the two groups during treatment were more with fever, chills, bone marrow suppression and gastrointestinal reactions, there were no significant difference compared between the two groups. Conclusion The application of zoledronic acid combined with chemotherapy in NSCLC bone metastasis can improve the clinical efficacy and relieve pain, and does not increase the occurrence of adverse reactions. The mechanism of its action is related to the reduction of the expression of inflammatory factors.
作者
陈滔
谭兴春
CHEN Tao;TAN Xingchun(Orthopedics Department,Kaizhou District People's Hospital of Chongqing, Chongqing 405400, China)
出处
《药物评价研究》
CAS
2019年第6期1198-1201,共4页
Drug Evaluation Research
关键词
唑来膦酸
化疗
非小细胞肺癌
骨转移
炎性因子
zoledronic acid
chemotherapy
non-small cell lung cancer
bone metastasis
inflammatory factors
